Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background Immune checkpoint inhibitors (ICIs) have been increasingly used in cancer treatment, and a subset of patients undergo pseudoprogression. Recognizing the incidence of pseudoprogression is critical for clinical practice. Purpose To evaluate by systematic review and meta-analysis the incidence of pseudoprogression in cancer treatment with ICIs, and compare the incidence according to response criteria, tumor types, and immunotherapeutic agents. Materials and Methods Medline and Embase were searched to identify relevant studies published before December 31, 2018. Clinical trials, post hoc analysis of clinical trials, and prospective studies on ICI treatment in patients with malignant solid tumors were included. Pooled incidence of pseudoprogression for all included studies, per definition of pseudoprogression, cancer type, and drug type, was obtained by random-effects models with inverse variance weighting model. Results Seventeen studies with 3402 patients were analyzed. The pooled incidence of pseudoprogression was 6.0% (95% confidence interval: 5.0%, 7.0%). The definition of pseudoprogression were divided into four categories: progressive disease followed by partial response (PR) or complete response (CR) but not stable disease (SD) with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (six studies); progressive disease followed by SD or PR or CR with RECIST 1.1 (five studies); progressive disease followed by SD or PR or CR with RECIST 1.0 (three studies); and progressive disease followed by SD or PR or CR with immune-related response criteria (irRC) (three studies). Incidence of pseudoprogression varied from 4.5% to 8.0% per definition, ranged from 5.0% to 7.0% per cancer type, and was 5.6% with the monotherapy of programmed cell death-1 inhibitor. Conclusion The overall incidence of pseudoprogression was 6.0% and was less than 10% in subgroup analyses according to the definitions of pseudoprogression, cancer type, and immune checkpoint inhibitor type. Varying definitions across trials and studies indicates the need for uniform criteria of pseudoprogression for solid tumors. © RSNA, 2020 Online supplemental material is available for this article. See also the article by Dodd and MacDermott in this issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given the accumulating evidence of 'pseudoprogression' in a minority of ICB recipients 62”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Research works printed but not linked: 1
- 10. Identifying Markers for Clinical Outcome and Treatment Decisions. Clin Cancer Res 2017;23(16):4671-4679.
Cited by
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
“90,91 Longitudinal monitoring for emergent resistance mutations.”
A gut microbial signature for combination immune checkpoint blockade across cancer types
Gunjur, A., Shao, Y., Rozday, T., Klein, O., Mu, A., Haak, B. W., Markman, B., Kee, D., Carlino, M. S., Underhill, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02823-z · Cited by 165
“Given the accumulating evidence of ‘pseudoprogression’ in a minority of ICB recipients 62 , under the trial protocol, ICB therapy could extend beyond RECIST 1.1-defined PD if there was investigator-assessed clinical benefit and good participant tolerance of the study drugs until there was evidence…”
InfluentialImmune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
Pinter, M., Scheiner, B., & Pinato, D. J. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00147-4 · Cited by 155
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas
Brastianos, P. K., Kim, A. E., Giobbie‐Hurder, A., Lee, E. Q., Wang, N., Eichler, A. F., Chukwueke, U. N., Forst, D. A., Arrillaga‐Romany, I., Dietrich, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29052-7 · Cited by 121
“This phenomenon has been described with solid tumors of diverse histologies, including meningioma, undergoing treatment with ICI 22,23 .”
Multiparametric MRI for characterization of the tumour microenvironment
Hoffmann, E., Masthoff, M., Kunz, W. G., Seidensticker, M., Bobe, S., Gerwing, M., Berdel, W. E., Schliemann, C., Faber, C., & Wildgruber, M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00891-1 · Cited by 113
“These intratumoural changes can lead to an initial increase in lesion size, also known as pseudoprogression, followed by a partial or complete response 154 .”
Li, H., Luo, Q., Zhang, H., Ma, X., Gu, Z., Gong, Q., & Luo, K. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00437b · Cited by 97
Emerging Trends in Immunotherapy for Cancer
Mishra, A. K., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022) · Diseases · doi:10.3390/diseases10030060 · Cited by 88
Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006947 · Cited by 82
How to use liquid biopsies to treat patients with cancer
Mattos‐Arruda, L. D., & Siravegna, G. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100060 · Cited by 76
“Another scenario where ctDNA may be useful is to rule out true progression from pseudoprogression, which has 5%-10% incidence with immuno-oncology agents in solid tumors.(32) A recent study including 29 melanoma patients showed the ability of ctDNA to differentiate between true progression and pseudoprogression to ant…”
BackgroundTreatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 70
“This effect is rare, occurring in 6% of patients across all tumour types 145 .”
Fournier, L. S., de Geus‐Oei, L., Regge, D., Oprea‐Lager, D. E., D’Anastasi, M., Bidaut, L. M., Bäuerle, T., Lopci, E., Cappello, G., Lecouvet, F. E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.800547 · Cited by 69
Al-Showbaki, L., Wilson, B. E., Tamimi, F., Moltó, C., Mittal, A., Cescon, D. W., & Amir, E. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005854 · Cited by 65
18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer
Hughes, D. J., Subesinghe, M., Taylor, B. P., Billè, A., Spicer, J. F., Papa, S., Goh, V., & Cook, G. (2022) · Radiology · doi:10.1148/radiol.212481 · Cited by 62
Filippi, L., Bianconi, F., Schillaci, O., Spanu, A., & Palumbo, B. (2022) · Diagnostics · doi:10.3390/diagnostics12040929 · Cited by 53
“In a recently published meta-analysis, the incidence of pseudo-progression in cancer patients treated with ICIs was reported to be 6–10%, more often occurring during therapy with ipilumumab [45].”
BackgroundLiberini, V., Laudicella, R., Capozza, M., Huellner, M. W., Burger, I. A., Baldari, S., Terreno, E., & Deandreis, D. (2021) · Molecules · doi:10.3390/molecules26082201 · Cited by 49
“[143] reported that the incidence according to tumor types were similar for the three more representative ones (6.”
Kim, P. H., Suh, C. H., Kim, H. S., Kim, K. W., Kim, D., Aizer, A. A., Rahman, R. M., Guenette, J. P., & Huang, R. Y. (2020) · European Radiology · doi:10.1007/s00330-020-07514-0 · Cited by 44
“The pooled incidence of pseudoprogression seems to be much higher in patients with glioblastoma (36%; 95% CI, 33–40%) [52] than in patients with metastasis from other solid tumors (6%; 95% CI, 5–7%) [53].”
BackgroundSelf-citationPark, H. J., Kim, G. H., Kim, K. W., Lee, C. W., Yoon, S., Chae, Y. K., Tirumani, S. H., & Ramaiya, N. H. (2021) · Cancers · doi:10.3390/cancers13010120 · Cited by 42
“However, controversy remains as the incidence of pseudoprogression is low, less than 10% [23] Treatment beyond progression might have risks of continuing futile treatment and delaying switch to other treatment options in patients with true progression.”
BackgroundResultInfluentialSelf-citationIn vivo bioluminescence imaging of granzyme B activity in tumor response to cancer immunotherapy
Chen, M., Zhou, K., Dai, S., Tadepalli, S., Balakrishnan, P. B., Xie, J., Rami, F. E., Dai, T., Cui, L., Idoyaga, J., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.08.006 · Cited by 43
Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
Bertoli, E., Carlo, E. D., Basile, D., Zara, D., Stanzione, B., Schiappacassi, M., Conte, A. D., Spina, M., & Bearz, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310803 · Cited by 40
“One challenge of immuno-oncology is undoubtedly the interpretation of pseudo progression, early progression, and delayed radiological response [191].”
BackgroundLiberini, V., Mariniello, A., Righi, L., Capozza, M., Delcuratolo, M. D., Terreno, E., Farsad, M., Volante, M., Novello, S., & Deandreis, D. (2021) · Cancers · doi:10.3390/cancers13184543 · Cited by 36
“[147], the pooled incidence of pseudo-progression was calculated to be around 5.”
Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study
Remde, H., Schmidt-Pennington, L., Reuter, M., Landwehr, L., Jensen, M., Lahner, H., Kimpel, O., Altieri, B., Laubner, K., Schreiner, J., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad054 · Cited by 31
Frank, M. S., Andersen, C. S. A., Ahlborn, L. B., Pallisgaard, N., Bødtger, U. C. S., & Gehl, J. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0258 · Cited by 28
Immunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice
Schmidt, M., & Heimes, A.-S. (2021) · Cancers · doi:10.3390/cancers13194883 · Cited by 30
“In addition, infiltration of immune cells may lead to an initial enlargement of metastases, a so-called pseudoprogression [52].”
BackgroundCirculating tumor DNA in clinical trials for solid tumors: Challenges and current applications
Parisi, C., Tagliamento, M., Belcaid, L., Aldea, M. D., Bayle, A., Remon-Masip, J., Italiano, A., Planchard, D., Besse, B., & Barlési, F. (2023) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2023.100007 · Cited by 31
“Nevertheless, identifying patients with MRD [90], early progression [91] or interpreting response to immune check point inhibitors (ICIs) with imaging is challenging [92].”
Chen, M., Chen, Z., Castillo, J. B., Cui, L., Zhou, K., Shen, B., Xie, J., Chin, F. T., & Rao, J. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05297-0 · Cited by 30
Mönch, S., Heimer, M. M., Winkelmann, M., Guertler, A., Schlaak, M. S., Tufman, A., Khaled, N. B., Toni, E. D., Westphalen, C. B., von Bergwelt‐Baildon, M., et al. (2023) · Cancer Imaging · doi:10.1186/s40644-023-00580-9 · Cited by 26
“The incidence of PsPD amounts to 2–10%, depending on tumor entity and PsPD definition [9, 11].”
BackgroundKim, N., Lee, E. S., Won, S. E., Yang, M., Lee, A. J., Shin, Y., Ko, Y., Pyo, J., Park, H. J., & Kim, K. W. (2022) · Korean Journal of Radiology · doi:10.3348/kjr.2022.0225 · Cited by 25
“In general, pseudoprogression has an incidence of less than 10% in solid tumors and lymphomas [37].”
BackgroundSelf-citationMeyers, B. M., Knox, J. J., Liu, D. M., McLeod, D., Ramjeesingh, R., Tam, V. C., & Lim, H. J. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102584 · Cited by 25
Disis, M. L., Adams, S. F., Bajpai, J., Butler, M. O., Curiel, T. J., Dodt, S. A., Doherty, L., Emens, L. A., Friedman, C. F., Gatti-Mays, M. E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006624 · Cited by 27
Sang, J., & Ye, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1268331 · Cited by 25
“Pseudoprogression and hyperprogression are two different response patterns to immunotherapy (89), which are related to changes in the TIME, such as T cell in fi ltration (90).”
BackgroundWen, Q., Qiu, L., Qiu, C., Che, K., Zeng, R., Wang, X., Cao, P., Xing, L., Yang, Z., & Yu, J. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217881 · Cited by 25
Masse, M., Chardin, D., Tricarico, P., Ferrari, V., Martin, N., Otto, J., Darcourt, J., Comte, V., & Humbert, O. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06794-8 · Cited by 23
“Previous studies have shown that PsPD occurs in approximately 7% of patients monitored by CT scan [28, 29] and approximately 10% of patients monitored by [ 18 F]FDG-PET/ CT imaging [25].”
BackgroundImaging of Immune Checkpoint Inhibitor Immunotherapy for Non–Small Cell Lung Cancer
Shroff, G. S., Strange, C. D., Ahuja, J., Altan, M., Sheshadri, A., Ünlü, E., Truong, M. T., & Vlahos, I. (2022) · Radiographics · doi:10.1148/rg.220108 · Cited by 23
Hassel, J. C., Zimmer, L., Sickmann, T., Eigentler, T., Meier, F. E., Mohr, P., Pukrop, T., Roesch, A., Vordermark, D., Wendl, C. M., et al. (2023) · Cancers · doi:10.3390/cancers15133448 · Cited by 24
“…reveal the overall incidence Meta-analyses reveal the overall incidence of pseudoprogression in solid tumors to be about 6% during or after ICI [21] but up to date, there are no predictive biological or clinical markers available [22]. of pseudoprogression in solid tumors to be about 6% during…”
Lee, A. J., Kim, K. W., Cho, Y. C., Ko, Y., Sung, Y. S., Shin, Y., Lee, J., & Kim, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112257 · Cited by 21
“0) [6], which may be attributable to the characteristics of lymphoid malignancies and immunotherapy.”
BackgroundSelf-citationPark, H., Tseng, S.-C., Sholl, L. M., Hatabu, H., Awad, M. M., & Nishino, M. (2022) · Radiology · doi:10.1148/radiol.220585 · Cited by 22
Self-citationGenome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer
Hruban, C., Bruhm, D. C., Chen, I. M., Koul, S., Annapragada, A. V., Vulpescu, N. A., Short, S. B., Theile, S., Boyapati, K., Alipanahi, B., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads5002 · Cited by 19
“CT scans can be misleading in patients treated with immunotherapy as immune infiltration can mask therapeutic response or appear as pseudo-progression in radiographs ( 15 ).”
Approaches to Imaging Immune Activation Using PET
Parihar, A. S., Pant, N., Heidari, P., Fong, L. H., & Iravani, A. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268289 · Cited by 18
“…cytotoxic T-lymphocyte – associated antigen 4 inhibitors, such as ipilimumab, compared with the anti – programmed death protein 1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1) inhibitors, and is seen more often with combination immunotherapies than with single-agent immunotherapy ( 20 ).”
Murad, V., Kohan, A. A., Ortega, C., Prica, A. A., Veit‐Haibach, P., & Metser, U. (2024) · American Journal of Roentgenology · doi:10.2214/ajr.23.30301 · Cited by 20
Wong, A. S. C., Vellayappan, B. A., Cheng, L. T. J., Zhao, J. J., Muthu, V., Asokumaran, Y., Low, J.-L., Lee, M., Huang, Y., Kumarakulasinghe, N. B., et al. (2021) · Cancers · doi:10.3390/cancers13071689 · Cited by 20
“%) of the incidence of pseudoprogression across tumor types [6,15], but we found the incidence in our RCC patients to be higher (32.6”
InfluentialArtificial intelligence for response prediction and personalisation in radiation oncology
Zwanenburg, A., Price, G. J., & Löck, S. (2024) · Strahlentherapie und Onkologie · doi:10.1007/s00066-024-02281-z · Cited by 19
Jin, W., & Luo, Q. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105499 · Cited by 15
A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
Watanabe, Y., Ogawa, M., Tamura, Y., Suda, S., Kaneko, M., Kumagawa, M., Hirayama, M., Matsumoto, N., Yamamoto, T., & Moriyama, M. (2021) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096211058489 · Cited by 14
The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma
Bersanelli, M., Buti, S., & Rizzo, M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1861941 · Cited by 13
“Furthermore, additional issues must be taken into account: clinical benefit despite radiological progression, often subtending a situation of pseudoprogression in the case of immunotherapy, and requiring the subsequent radiological confirmation [26]; slow progression with clinical benefit maintenance, often deserving…”
BackgroundOdagiri, N., Tamori, A., Kotani, K., Motoyama, H., Kawamura, E., Hagihara, A., Fujii, H., Uchida‐Kobayashi, S., Enomoto, M., & Kawada, N. (2023) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-023-01761-6 · Cited by 13
“A recent meta-analysis reported that the overall incidence of pseudoprogression was 6% to less than 10% [8].”
BackgroundNormanno, N., Caridi, V., Fassan, M., Avallone, A., Ciardiello, F., & Pinto, C. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00231 · Cited by 12
Smith, D. A., Radzinsky, E., Tirumani, S. H., Güler, E., Petraszko, A. M., Kikano, E. G., Hoimes, C. J., & Ramaiya, N. H. (2020) · American Journal of Roentgenology · doi:10.2214/ajr.20.24758 · Cited by 13
Immune checkpoint inhibitors in older patients with solid tumors: Real-world experience from India
Abraham, G., Jobanputra, K. N., Noronha, V., Patil, V. M., Menon, N. S., Gattani, S. C., & Prabhash, K. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_86_21 · Cited by 13
Shigefuku, R., Yoshikawa, K., Tsukimoto, M., Owa, H., Tamai, Y., Tameda, M., Ogura, S., Sugimoto, R., Tanaka, H., Eguchi, A., et al. (2022) · Internal Medicine · doi:10.2169/internalmedicine.9701-22 · Cited by 12
“A systematic review and metaanalysis reported that the overall incidence of pseudopro- gression was 6.0% in clinical trials of cancer patients on ICIs (5).”
BackgroundInfluentialMorrissey, S., Vasconcelos, A. G., Wang, C. L., Wang, S., & Cunha, G. M. (2024) · Clinical Oncology · doi:10.1016/j.clon.2024.06.002 · Cited by 11
Practical Pharmacokinetic–Pharmacodynamic Models in Oncology
Guan, S., Tu, M., & Yu, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111452 · Cited by 13
“…small-molecule agents, immune checkpoint inhibitors such as pembrolizumab, nivolumab, and ipilimumab can induce nonlinear and time-dependent response patterns, including pseudo-progression and delayed tumor shrinkage, which are difficult to describe with traditional PK–PD models alone [111–113].”
Kawakami, N., Saito, H., Takahashi, S., Kajie, S., Kato, R., Shimaya, K., Wakai, Y., Saito, K., & Sakashita, M. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.01.003 · Cited by 11
Samuelly, A., Stefano, R. F. D., Turco, F., Delcuratolo, M. D., Pisano, C., Saporita, I., Calabrese, M., Carfì, F. M., Tucci, M., & Buttigliero, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020307 · Cited by 10
“…data from two phase III trials of nivolumab or nivolumab plus ipilimumab in small-cell lung cancer and nivolumab alone in gastric or gastroesophageal junction cancer and found no evidence of HPD in either the overall analysis or the non-responder population compared to the placebo cohorts [68].”
BackgroundManson, G., Amaeshi, L. C., Mokrane, F., Lopci, E., Aide, N., Vercellino, L., Houot, R., & Dercle, L. (2022) · European Radiology · doi:10.1007/s00330-022-08669-8 · Cited by 10
“In solid tumors [23], ICI treatment leads to pseudoprogression in 5– 10% of patients [23, 24].”
BackgroundMatsuki, R., Okano, N., Hasui, N., Kawaguchi, S., Momose, H., Kitahama, K., Nagahama, K., Kogure, M., Suzuki, Y., Nagashima, F., et al. (2022) · Liver Cancer · doi:10.1159/000527250 · Cited by 10
Balbi, M., Mazzaschi, G., Leo, L., Tor, L. M. D., Milanese, G., Marrocchio, C., Silva, M., Mura, R., Favia, P., Bocchialini, G., et al. (2024) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000801 · Cited by 10
Maurer, A. B., Clerici, G., Schaab, J. A., Cheng, P. F., Mihic‐Probst, D., Mader, C. E., Messerli, M., Huellner, M. W., Dummer, R., & Dimitriou, F. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01497-8 · Cited by 9
“Further, pseudoprogres-sion in imaging under immunotherapeutic treatments is a known phenomenon and could have impacted the results of the radiological response assessment [38, 43].”
Steimle, A. K., Cho, S. Y., Menon, N., Jeraj, R., Birbrair, A., Albertini, M. R., & Ma, V. T.-L. (2025) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000569 · Cited by 7
Cao, Q., Han, L., Sun, P.-F., Lü, D., Tian, B., Jiao, K.-F., Tian, J.-C., Wang, Y.-X., Jia, J.-S., Zhang, Z., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101557 · Cited by 8
Multimodal Imaging Approach for Tumor Treatment Response Evaluation in the Era of Immunotherapy
Lee, G., Moon, S. H., Kim, J., Jeong, D. Y., Choi, J., Choi, J. Y., & Lee, H. Y. (2024) · Investigative Radiology · doi:10.1097/rli.0000000000001096 · Cited by 7
Zhao, J., & Zhao, M. (2023) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000479 · Cited by 7
Eertink, J. J., Bahce, I., Waterton, J. C., Huisman, M. C., Boellaard, R., Wunder, A., Thiele, A., & van Oordt, C. W. M. D. H. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1347267 · Cited by 8
Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor
Chon, E., Morsey, M., Katz, T., Yamada, K., Bailey, D., Bergman, P. J., Burr, H., Clifford, C. A., Heeb, H., Manley, C. A., et al. (2026) · Journal of Veterinary Internal Medicine · doi:10.1093/jvimsj/aalag098 · Cited by 9
Response evaluation to systemic therapy in HCC: Current challenges and future perspectives
Matute‐González, M., Ronot, M., Chernyak, V., Sangro, B., & Rimola, J. (2025) · Hepatology · doi:10.1097/hep.0000000000001621 · Cited by 6
“[65] However, this analysis did not include HCC-specific studies, for which available data are sparse and mostly limited to case reports.”
Mottaghy, F. M., Hertel, F., & Beheshti, M. (2021) · Methods · doi:10.1016/j.ymeth.2021.02.011 · Cited by 6
Pei, J., Xu, H., Dong, Q., Gao, Y., Huang, Y., Xie, X., Huang, L., Qu, B., Chen, Y., Yang, S.-X., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002795 · Cited by 5
“Pseudo-progression refers to clinical tumor progression confirmed as a treatment response on pathology [38] .”
Nishino, M., Hong, F., Ricciuti, B., Hatabu, H., & Awad, M. M. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00478 · Cited by 5
“The result further confirms that pseudoprogression is a very rare event, especially in advanced NSCLC patients treated with PD-1 inhibitor monotherapy, including the first-line pembrolizumb.(14-17,30,34) The observation also support the choice of RECIST1.”
Self-citationA Multidisciplinary Treatment Strategy With Conversion Surgery for Hepatocellular Carcinoma
Shiozaki, H., Furukawa, K., Haruki, K., Matsumoto, M., Uwagawa, T., Onda, S., Yamahata, Y., Ishizaki, S., Abe, K., FUJIOKA, S., et al. (2023) · Anticancer Research · doi:10.21873/anticanres.16329 · Cited by 5
The role of clinical imaging in oncology drug development: progress and new challenges
Murphy, P. S., Galette, P., van der Aart, J., Janiczek, R. L., Patel, N., & Brown, A. P. (2023) · British Journal of Radiology · doi:10.1259/bjr.20211126 · Cited by 5
Shah, J. V., Siebert, J. N., Zhao, X., He, S., Riman, R. E., Tan, M. C., Pierce, M. C., Lattime, E. C., Ganapathy, V., & Moghe, P. V. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300092 · Cited by 5
End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?
Degtyarev, E., Bolaños, N., Brody, J., Buchbinder, A., Buyse, M. E., Fuchs, M., Halabi, S., Hemmings, R., Masood, A., Newsome, S., et al. (2024) · Future Oncology · doi:10.1080/14796694.2024.2357537 · Cited by 5
Chen, M. I.-C., Smith, D. A., Yoon, J. G., Vos, D. J., Kikano, E. G., Tirumani, S. H., & Ramaiya, N. H. (2022) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001315 · Cited by 5
Fietz, S., Diekmann, E., de Vos, L., Zarbl, R., Hunecke, A., Glosch, A.-K., Färber, M., Sirokay, J. D., Hoffmann, F., Fröhlich, A., et al. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvad230 · Cited by 6
Evaluation of Response to Immune Checkpoint Inhibitors Using a Radiomics, Lesion-Level Approach
Song, C., Park, H., Lee, H. Y., Lee, S., Ahn, J., & Lee, S. (2021) · Cancers · doi:10.3390/cancers13236050 · Cited by 7
“1 for immune-based therapeutics (termed iRECIST), have been proposed as alternatives [8–10], but these criteria only consider pseudoprogression [11].”
BackgroundSelf-citationLi, F., Lu, H., Zhao, D. F., & Shen, Z. (2023) · Journal of International Medical Research · doi:10.1177/03000605231174973 · Cited by 5
“It is mainly due to the activation and proliferation of large numbers of CD8þ T cells around the tumour at the initial stage of medication, which leads to the progression observed on a simple imaging assessment that can be checked by puncture biopsy of the tumour lesion.(39,40) The current patient was recommended to h…”
BackgroundHuang, W., Son, M. H., Hà, L. N., Kang, L., & Cai, W. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06680-3 · Cited by 5
“Furthermore, it is expected to play a critical role in drug development and trial design [38].”
Xu, H., Zhang, J., Wei, Z., Wang, X., Yang, M.-F., & Yang, X. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012672 · Cited by 4
“…imaging modalities like CT and MRI, assess treatment efficacy based on macroscopic parameters like tumor volume and tissue density, but suffer from delayed feedback on therapeutic outcomes and the inability to recognize tumor pseudoprogression, 7 8 potentially delaying optimal patient management.”
Fedorova, L. V., Lepik, K. V., Gusak, A., Kotselyabina, P. V., Moiseev, I., Baykov, V., Mikhailova, N. B., & Kulagin, A. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06091-2 · Cited by 4
“It was concluded that the use of standard response criteria would have resulted in underestimation of response in 15% of patients, potentially leading to premature discontinuation of effective therapy [12].”
Heimer, M. M., Cimic, A., Kloiber-Langhorst, S., Antons, M. J., Stueckl, J., Hirner-Eppeneder, H., Kunz, W. G., Dietrich, O., Ricke, J., Herr, F. L., et al. (2025) · European Radiology Experimental · doi:10.1186/s41747-025-00597-8 · Cited by 5
“This phenomenon, known as pseudoprogression, has been documented in numerous studies and has been reported to reach up to 6 – 10% in melanoma patients and appears as a relevant challenge in early response assessment [5, 12, 13].”
Cao, P., & Yang, X. (2025) · Cancer Medicine · doi:10.1002/cam4.71251 · Cited by 4
Wu, M. J., Liu, J., Seery, S., Meng, X., & Yue, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.646085 · Cited by 4
iRECIST: Response-Assessment von Immuntherapien
Lennartz, S., Nelles, C., & Persigehl, T. (2026) · Die Radiologie · doi:10.1007/s00117-025-01552-9 · Cited by 3
“Eine 2020 veröffentlichte Analyse schätzte die Ge-samtinzidenz der Pseudoprogression auf 6% [2], eine spätere Übersichtsarbeit auf ca.15%ein[3].”
Andersen, M. E., Nyhus, C. H., Szejniuk, W. M., Wahlstrøm, S., Timm, S., Pallisgaard, N., Madsen, M. G., Mikkelsen, M. D., Ahlborn, L. B., Gehl, J., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-100311 · Cited by 3
Nasu, I., Kondo, M., Uozumi, R., Takada, S., Nawata, S., Iihara, H., Okumura, Y., Takemoto, M., Mino, K., Sasaki, T., et al. (2023) · Journal of Cancer · doi:10.7150/jca.80517 · Cited by 3
“A previous study reported that ICIs have a carry-over effect [26], and there is sometimes a pseudo-progression before ICIs prove to be effective [27].”
BackgroundImaging Findings of Complications of New Anticancer Drugs
Jang, J. S., Park, H. J., Suh, C. H., Won, S. E., Lee, E. S., Kim, N., Lee, D., & Kim, K. W. (2025) · Korean Journal of Radiology · doi:10.3348/kjr.2024.0195 · Cited by 3
Self-citationBertaux, M., Luo, C., Radulescu, C., Beuzeboc, P., Landais, C., Touche, P., Abraham, C. L., Seban, M. H., Camps, È., Faucheron, A., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050701 · Cited by 3
F-18 Fluciclovine PET-CT Findings and Pseudoprogression on Immunotherapy
Poindexter, B. C., Kasireddy, N. M., & Molchanova-Cook, O. P. (2022) · Cureus · doi:10.7759/cureus.30380 · Cited by 3
“The phenomenon of pseudoprogression related to the use of immunotherapy was extensively described in the literature for treatments with checkpoint inhibitors (for example, PD-1 targeting immunotherapy with pembrolizumab) [9].”
BackgroundWee, M. E. U., Hung, C., Tsai, M., Chen, C., & Kuo, Y. (2025) · Cureus · doi:10.7759/cureus.86905 · Cited by 2
“%) among patients receiving ICI therapy [6].”
State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder Cancer
Eid, S. B., Al-Yousef, A. S., Kim, K. W., Yoon, S., Nawfal, R., Bellmunt, J., Choueiri, T. K., & Krajewski, K. M. (2025) · Korean Journal of Radiology · doi:10.3348/kjr.2025.0416 · Cited by 2
Self-citationZheng, S., Harada, Y., Morodomi, Y., Yasuda, N., Ishimoto, K., & Yonemitsu, Y. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014300 · Cited by 2
“All cells were cultured under a humidified atmosphere containing 5% CO 2 at 37°C.”
Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment
Bernstock, J. D., Spanehl, L., & Chiocca, E. A. (2026) · Nature Cancer · doi:10.1038/s43018-026-01153-y · Cited by 2
“…may not fully reflect the therapeutic impact of OVs and GTs. Pseu-doprogression, an apparent tumor enlargement caused by immune infiltration and inflammation, is frequently observed with immuno-therapies and can potentially lead to inappropriate treatment decisions if misinterpreted 157,158 .”
The radiological appearances of lung cancer treated with immunotherapy
Milanese, G., Mazzaschi, G., Ledda, R. E., Balbi, M., Lamorte, S., Caminiti, C., Colombi, D., Tiseo, M., Silva, M., & Sverzellati, N. (2022) · British Journal of Radiology · doi:10.1259/bjr.20210270 · Cited by 7
Mander, E. S., Merrick, C., Nicholson, H. A., Lord, H., Ferguson, M., & Smith, G. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076715 · Cited by 2
Amrane, K., Meur, C. L., Thuillier, P., Kamga, J. D., Alemany, P., Chauvelot, F., Niel, C., Bellange, A., & Abgral, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1243208 · Cited by 2
Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition
Wu, L. W., Tao, J. J., McDonnell, D. E., & Izar, B. (2024) · Melanoma Research · doi:10.1097/cmr.0000000000000974 · Cited by 2
[Advances in Pseudoprogression of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer].
Tong, Y., Long, Y., Zhang, F., & Li, J. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2024.101.10 · Cited by 2
Assessing Outcomes in NSCLC: Radiomic analysis, kinetic analysis and circulating tumor DNA
Maniar, A. B., Wei, A. Z., Dercle, L., Bien, H., Fojo, T., Bates, S. E., & Schwartz, L. H. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.002 · Cited by 2
Nishino, M., Wang, X., Ricciuti, B., Tseng, S.-C., Park, H., Alessi, J. V., Vaz, V. R., Hatabu, H., Lin, X., Christiani, D. C., et al. (2023) · European Radiology · doi:10.1007/s00330-023-09658-1 · Cited by 2
“The choice is based on the fact that RECIST remains to be the primary response criteria used for the published trials of ICI including PD-1 inhibitors [13].”
BackgroundMethodInfluentialSelf-citationHAYASHI, K., Furuta, M., Furusawa, K., Hamaguchi, T., Watanabe, M., Inokuchi, Y., ONUMA, S., HASHIMOTO, I., Suematsu, H., Nagasawa, S., et al. (2023) · Anticancer Research · doi:10.21873/anticanres.16452 · Cited by 2
Dodd, J. D., & MacDermott, R. (2020) · Radiology · doi:10.1148/radiol.2020202842 · Cited by 2
Metadata
- Authors
- Park, H. J., Kim, K. W., Pyo, J., Suh, C. H., Yoon, S., Hatabu, H., & Nishino, M.
- Affiliations
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- Radiology
- Published
- 2020-10
- Volume
- 297
- Issue
- 1
- Pages
- 87-96
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- PMC
- PMC7526949
- OpenAlex
- W3047211233
- Cited by
- 162
- References
- 45
- Citations by year
- 2026: 31 · 2025: 26 · 2024: 22 · 2023: 31 · 2022: 27 · 2021: 19 · 2020: 5
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Radiology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Research Foundation of Korea (2017R1A2B3011475)
- National Cancer Institute (R01CA203636)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pseudoprogression, immune checkpoint inhibitors, solid tumors, incidence, RECIST 1.1, immune-related response criteria, PD-1 inhibitors, tumor response assessment, cancer immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Humans, Neoplasms, Disease Progression, Response Evaluation Criteria in Solid Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.